How the BRAF V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How the BRAF V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications
Authors
Keywords
-
Journal
Gastroenterology Research and Practice
Volume 2018, Issue -, Pages 1-14
Publisher
Hindawi Limited
Online
2018-11-27
DOI
10.1155/2018/9250757
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
- (2018) Rona Yaeger et al. CANCER CELL
- Treatment and Survival Outcome of BRAF -Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study
- (2018) Hamzeh Kayhanian et al. Clinical Colorectal Cancer
- BRAF-mutant colorectal cancer, a different breed evolving
- (2018) Eleonora Lai et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis
- (2018) Tamsin R M Lannagan et al. GUT
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients
- (2018) José María Sayagués et al. Oncotarget
- The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern
- (2018) Thiru Prasanna et al. ACTA ONCOLOGICA
- CpG Island Methylation in Sessile Serrated Adenomas Increases With Age, Indicating Lower Risk of Malignancy in Young Patients
- (2018) Cheng Liu et al. GASTROENTEROLOGY
- Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
- (2017) Jeremy C. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of APC in WNT pathway activation in serrated neoplasia
- (2017) Jennifer Borowsky et al. MODERN PATHOLOGY
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
- (2017) Zhan Yao et al. NATURE
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
- (2017) S. Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Investigating the poor outcomes of BRAF -mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials
- (2016) J.F. Seligmann et al. ANNALS OF ONCOLOGY
- BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
- (2016) David Barras et al. CLINICAL CANCER RESEARCH
- Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma
- (2016) Minggang Fang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
- (2016) D. S. Hong et al. Cancer Discovery
- RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis
- (2016) Catherine E. Bond et al. Oncotarget
- Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups
- (2015) Catherine E Bond et al. BMC CANCER
- KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
- (2015) S Renaud et al. BRITISH JOURNAL OF CANCER
- Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer
- (2015) T T Seppälä et al. BRITISH JOURNAL OF CANCER
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
- (2015) Zhan Yao et al. CANCER CELL
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival
- (2015) Amanda I. Phipps et al. GASTROENTEROLOGY
- Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
- (2015) Frank A. Sinicrope et al. GASTROENTEROLOGY
- Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma
- (2015) Mark Bettington et al. GUT
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy
- (2015) Patricia Llovet et al. Molecular Diagnosis & Therapy
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
- (2015) L. G. Ahronian et al. Cancer Discovery
- Keratin 7 expression in colorectal cancer - freak of nature or significant finding?
- (2015) Lars Harbaum et al. HISTOPATHOLOGY
- PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations
- (2015) Katsuhiko Nosho et al. NEOPLASIA
- Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)
- (2014) J. Goldstein et al. ANNALS OF ONCOLOGY
- DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability
- (2014) Yuta Muto et al. BMC CANCER
- Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists
- (2014) Ana-Luisa Silva et al. BMC CANCER
- BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
- (2014) Rona Yaeger et al. CANCER
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- Isocitrate dehydrogenase 1R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype
- (2014) VLJ Whitehall et al. Epigenetics
- BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression
- (2014) Michael S. Landau et al. HUMAN PATHOLOGY
- Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis
- (2014) Jia-Huei Tsai et al. MODERN PATHOLOGY
- A clinicopathological and molecular analysis of 200 traditional serrated adenomas
- (2014) Mark L Bettington et al. MODERN PATHOLOGY
- The BRAF Oncoprotein Functions through the Transcriptional Repressor MAFG to Mediate the CpG Island Methylator Phenotype
- (2014) Minggang Fang et al. MOLECULAR CELL
- Microsatellite Stable Colorectal Cancers Stratified by the BRAF V600E Mutation Show Distinct Patterns of Chromosomal Instability
- (2014) Catherine E. Bond et al. PLoS One
- Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies
- (2014) Jeanne Tie et al. Targeted Oncology
- The CIMP Phenotype inBRAFMutant Serrated Polyps from a Prospective Colonoscopy Patient Cohort
- (2014) Winnie C. Fernando et al. Gastroenterology Research and Practice
- Loss of CDX2/CK20 Expression Is Associated With Poorly Differentiated Carcinoma, the CpG Island Methylator Phenotype, and Adverse Prognosis in Microsatellite-unstable Colorectal Cancer
- (2013) Jung Ho Kim et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention
- (2013) Roland Rad et al. CANCER CELL
- PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer
- (2013) F. L. Day et al. CLINICAL CANCER RESEARCH
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- Targeting BRAF in melanoma: Biological and clinical challenges
- (2013) Mario Mandalà et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
- (2013) F. Loupakis et al. EUROPEAN JOURNAL OF CANCER
- Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency
- (2013) Heather Dawson et al. INTERNATIONAL JOURNAL OF CANCER
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- Epigenetic and genetic features of 24 colon cancer cell lines
- (2013) D Ahmed et al. Oncogenesis
- BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon
- (2012) Reetesh K. Pai et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics
- (2012) A. I. Phipps et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Influence of KRAS p.G13D Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab
- (2012) Pablo Gajate et al. Clinical Colorectal Cancer
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
- (2012) Carsten Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- The serrated pathway to colorectal carcinoma: current concepts and challenges
- (2012) Mark Bettington et al. HISTOPATHOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Chromosomal Instability in BRAF Mutant, Microsatellite Stable Colorectal Cancers
- (2012) Catherine E. Bond et al. PLoS One
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients
- (2011) J B Rawson et al. BRITISH JOURNAL OF CANCER
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Genome-scale analysis of aberrant DNA methylation in colorectal cancer
- (2011) T. Hinoue et al. GENOME RESEARCH
- Oncogenic PIK3CA mutations in colorectal cancers and polyps
- (2011) Vicki L.J. Whitehall et al. INTERNATIONAL JOURNAL OF CANCER
- p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers
- (2011) Catherine E. Bond et al. INTERNATIONAL JOURNAL OF CANCER
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features
- (2011) Inti Zlobec et al. JOURNAL OF PATHOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
- (2011) A. S. Little et al. Science Signaling
- The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
- (2010) A. Fariña-Sarasqueta et al. ANNALS OF ONCOLOGY
- Role of the Serrated Pathway in Colorectal Cancer Pathogenesis
- (2010) Barbara Leggett et al. GASTROENTEROLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
- (2009) M Koopman et al. BRITISH JOURNAL OF CANCER
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers
- (2008) Yvette Schwitalle et al. GASTROENTEROLOGY
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status
- (2008) Alessandro Lugli et al. MODERN PATHOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started